A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. - PubMed - NCBI

Similar Articles Added Earlier

• Halozyme Therapeutics - Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

  -FDA Approves Investigational Device Exemption (IDE) For Selection of Patients with HA-High Tumors- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301...

• Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

  Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk...

• Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

  Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

• JAMA Network | JAMA | Highlights

  In an open-label randomized trial that enrolled 449 patients with locally advanced pancreatic cancer that was controlled after induction chemotherapy, Hammel and colleagues found no significant difference in overall survival with chemoradiotherapy vs chemotherapy alone and found no significant...

• Dramatic remissions seen in immunotherapy trial of blood cancer patients

  Many patients with advanced blood cancers who are receiving experimental, “living” immunotherapy as part of a clinical trial are experiencing sustained remissions, according to preliminary results of the ongoing study at Fred Hutchinson Cancer Research Center.